SIRNA THERAPEUTICS GRANTED BROAD PATENT COVERING SIRNAS TARGETING HUNTINGTON'S DISEASE

Sirna Therapeutics, Inc. (Nasdaq: RNAI) the leading clinical-stage RNAi therapeutics company, announced today that the Australian Patent Office has issued a broad patent covering vector expressed siRNAs targeting the Huntington's disease (HD) gene. This is the first patent issued anywhere in the world which encompasses 'vector expressed' siRNAs targeting a disease gene. The patent claims, which are not limited to a specific siRNA sequence or structure, broadly cover any vector expressed siRNA used against the HD gene.

PR Newswire (http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/10-04-2005/0004159132&EDATE=)